Blog
RSS FeedPosted by Michael Wonder on 30 Jun 2022
Akeso's cadonilimab (PD-1/CTLA-4), the first dual immune checkpoint inhibitor to treat cancer, approved for marketing in China
29 June 2022 - Globally first dual immune checkpoint inhibitor bi-specific antibody approved for marketing. ...
Posted by Michael Wonder on 28 Jun 2022
Innovent and Lilly jointly announce the approval of Tyvyt (sintilimab) by China NMPA in combination with chemotherapy as first-line treatment of advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma
26 June 2022 - Innovent Biologics and Eli Lilly announced that the NMPA of China has approved the supplemental new drug ...
Posted by Michael Wonder on 23 Jun 2022
Innovent and Lilly jointly announce the approval of Tyvyt (sintilimab injection) by China NMPA in combination with chemotherapy as first-line treatment for oesophageal squamous cell carcinoma
20 June 2022 - Innovent Biologics and Eli Lilly today announced that the Center for Drug Evaluation of China's National ...
Posted by Michael Wonder on 14 Jun 2022
FDA’s treatment of China developed drugs spurs demands for multiregional clinical trials
14 June 2022 - China’s ambition to become a leader in the biopharma industry has been clear in the last ...
Posted by Michael Wonder on 12 Jun 2022
Zai Lab announces breakthrough therapy designations granted for repotrectinib in China
10 June 2022 - Breakthrough therapy designations granted for ROS1 positive non-small-cell lung cancer patients pretreated with one prior line of ...
Posted by Michael Wonder on 10 Jun 2022
Everest Medicines announces approval of Trodelvy in China for second-line metastatic triple negative breast cancer
10 June 2022 - Everest plans to launch commercial sales of Trodelvy in China in Q4, 2022. ...
Posted by Michael Wonder on 08 Jun 2022
CStone and Pfizer announce NMPA approval of sugemalimab in patients with unresectable stage III non-small cell lung cancer
6 June 2022 - Sugemalimab became the first anti-PD-1/PD-L1 monoclonal antibody approved for stage III NSCLC following concurrent or sequential chemoradiotherapy. ...
Posted by Michael Wonder on 02 May 2022
U.S. FDA declines to approve two more China tested drugs
2 May 2022 - The U.S. FDA declined to approve two China tested cancer treatments on Monday, raising concerns over ...
Posted by Michael Wonder on 18 Apr 2022
China NMPA approves tislelizumab for patients with second-line oesophageal squamous cell carcinoma
15 April 2022 - Tislelizumab is now approved for eight indications in China. ...
Posted by Michael Wonder on 07 Apr 2022
Innovent announces the approval of Pemazyre (pemigatinib) by the NMPA for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or rearrangement as confirmed by a validated diagnostic test that have progressed after at least one prior line of systemic therapy
6 April 2022 - Innovent Biologics announced that the National Medical Products Administration has approved Pemazyre (pemigatinib) for the treatment of ...
Posted by Michael Wonder on 04 Apr 2022
JW Therapeutics announces receipt of breakthrough therapy designation for Carteyva in mantle cell lymphoma in China
3 April 2022 - JW Therapeutics announced that the Center for Drug Evaluation of the National Medical Products Administration of China ...
Posted by Michael Wonder on 28 Mar 2022
China approves Takeda cancer drug
25 March 2022 - Japanese pharmaceutical company Takeda announced on Friday that brigatinib, an innovative lung cancer drug, has been approved ...
Posted by Michael Wonder on 21 Mar 2022
China’s NMPA grants greater access to rheumatology biosimilars
22 March 2022 - Since the start of 2022, China’s National Medicinal Products Agency has made strides to increase greater ...
Posted by Michael Wonder on 14 Mar 2022
InnoCare announces acceptance of supplemental new drug application for orelabrutinib in relapsed or refractory Waldenström's macroglobulinemia in China
14 March 2022 - InnoCare Pharma announced today that the Center for Drug Evaluation of the China National Medical Products Administration ...
Posted by Michael Wonder on 14 Mar 2022
China NMPA approves tislelizumab for patients with microsatellite instability-high or mismatch repair-deficient solid tumours
11 March 2022 - Tislelizumab is now approved in seven indications in China. ...